Gilead’s Kite pens 10-target CAR-T tech deal with MaxCyte

Gilead’s Kite Pharma has expanded its CAR-T agreement with MaxCyte. The revised deal gives Kite the chance to apply MaxCyte’s transfection technology to up to 10 targets.